ReviewClinical cancer research : an official journal of the American Association for Cancer Research2018
Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors.Clinical journal of gastroenterology · 2026Article
- Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.Current oncology (Toronto, Ont.) · 2025Article
- OCIAD2 as a novel prognostic and therapeutic biomarker for pancreatic cancer: A study based on transcriptomic signature and bioinformatics analysis.PLoS computational biology · 2025Article
- Personalized PDAC chip with functional endothelial barrier for tumour biomarker detection: A platform for precision medicine applications.Materials today. Bio · 2024Article
- Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022: A global perspective.World journal of gastrointestinal oncology · 2024Article
- Methylation ofJournal of translational internal medicine · 2024Article
- Single-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer.Science advances · 2022Article
- Recent Advancements in Mitochondria-Targeted Nanoparticle Drug Delivery for Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2022Review
- S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study.Frontiers in oncology · 2022Article
- Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology.Nature communications · 2021Article
- Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes.NPJ precision oncology · 2021Article
- Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas.Journal of cancer research and clinical oncology · 2020Review
- Potential of Exosomal microRNA-200b as Liquid Biopsy Marker in Pancreatic Ductal Adenocarcinoma.Cancers · 2020Article
- Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Article
- FF-10832 enables long survival via effective gemcitabine accumulation in a lethal murine peritoneal dissemination model.Cancer science · 2019Article
- Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.Radiation oncology (London, England) · 2019Review
- Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA.Molecular oncology · 2019Review
- [Pancreatic ductal adenocarcinoma].Der Internist · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Over the last decade, many of the major solid organ cancers have seen improvements in survival due to development of novel therapeutics and corresponding biomarkers that predict treatment efficacy or resistance. In contrast, favorable outcomes remain challenging in pancreatic ductal adenocarcinoma (PDAC), in part related to the lack of validated biomarkers for patient and treatment selection and thus optimal clinical decision-making. Increasingly, however, therapeutic development for PDAC is accompanied by bioassays to evaluate response and to study mechanism of actions with a corresponding increase in the number of trials in mid to late stage with integrated biomarkers. In addition, blood-based biomarkers that provide a measure of disease activity and allow for minimally invasive tumor analyses are emerging, including circulating tumor DNA, exosomes, and circulating tumor cells. In this article, we review potential biomarkers for currently approved therapies as well as emerging biomarkers for therapeutics under development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.